About Disheveled-associated activator of morphogenesis 2
Disheveled-associated activator of morphogenesis 2 (DAAM2) is a protein
from Homo sapiens identified by UniProt accession
Q86T65, 1068 residues long.
MolForge cross-references it against 0 known binders and
111 disease associations.
Target properties
| Protein name | Disheveled-associated activator of morphogenesis 2 |
|---|
| UniProt accession | Q86T65 |
|---|
| Gene | DAAM2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1068 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (111)
Diseases linked to this target (Open Targets).
- steroid-resistant nephrotic syndrome · score 0.46
- body height · score 0.46
- heel bone mineral density · score 0.45
- familial idiopathic steroid-resistant nephrotic syndrome · score 0.37
- cortical thickness · score 0.33
- neuroimaging measurement · score 0.32
- platelet count · score 0.30
- adolescent idiopathic scoliosis · score 0.28
- hypospadias · score 0.28
- intraocular pressure measurement · score 0.27
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q86T65-F1 | alphafold | PREDICTED | 79.47 | — |
Amino-acid sequence (1068 residues)
MAPRKRSHHG LGFLCCFGGS DIPEINLRDN HPLQFMEFSS PIPNAEELNI RFAELVDELD LTDKNREAMF ALPPEKKWQI YCSKKKEQED PNKLATSWPD YYIDRINSMA AMQSLYAFDE EETEMRNQVV EDLKTALRTQ PMRFVTRFIE LEGLTCLLNF LRSMDHATCE SRIHTSLIGC IKALMNNSQG RAHVLAQPEA ISTIAQSLRT ENSKTKVAVL EILGAVCLVP GGHKKVLQAM LHYQVYAAER TRFQTLLNEL DRSLGRYRDE VNLKTAIMSF INAVLNAGAG EDNLEFRLHL RYEFLMLGIQ PVIDKLRQHE NAILDKHLDF FEMVRNEDDL ELARRFDMVH IDTKSASQMF ELIHKKLKYT EAYPCLLSVL HHCLQMPYKR NGGYFQQWQL LDRILQQIVL QDERGVDPDL APLENFNVKN IVNMLINENE VKQWRDQAEK FRKEHMELVS RLERKERECE TKTLEKEEMM RTLNKMKDKL ARESQELRQA RGQVAELVAQ LSELSTGPVS SPPPPGGPLT LSSSMTTNDL PPPPPPLPFA CCPPPPPPPL PPGGPPTPPG APPCLGMGLP LPQDPYPSSD VPLRKKRVPQ PSHPLKSFNW VKLNEERVPG TVWNEIDDMQ VFRILDLEDF EKMFSAYQRH QKELGSTEDI YLASRKVKEL SVIDGRRAQN CIILLSKLKL SNEEIRQAIL KMDEQEDLAK DMLEQLLKFI PEKSDIDLLE EHKHEIERMA RADRFLYEMS RIDHYQQRLQ ALFFKKKFQE RLAEAKPKVE AILLASRELV RSKRLRQMLE VILAIGNFMN KGQRGGAYGF RVASLNKIAD TKSSIDRNIS LLHYLIMILE KHFPDILNMP SELQHLPEAA KVNLAELEKE VGNLRRGLRA VEVELEYQRR QVREPSDKFV PVMSDFITVS SFSFSELEDQ LNEARDKFAK ALMHFGEHDS KMQPDEFFGI FDTFLQAFSE ARQDLEAMRR RKEEEERRAR MEAMLKEQRE RERWQRQRKV LAAGSSLEEG GEFDDLVSAL RSGEVFDKDL CKLKRSRKRS GSQALEVTRE RAINRLNY
Explore Disheveled-associated activator of morphogenesis 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets